Melanotan 2: Research Studies

Melanotan 2 (MT-2) is a synthetic peptide analog of alpha-MSH,  Alpha-MSH/I-MSH, which is also known as alpha-melanocyte stimulating hormone is an important member of the melanocyte-stimulating  (MSHs) which stimulate melanogenesis, the pigmentation process for skin and hair in mammals. When administered in vitro, melanotan 2, which has the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 , displays super portent melanotropic activity.

Historical Development

Melanotan 2 was originally developed in the United States at the University of Arizona. As mentioned above, the body’s α-MSH hormone causes melanogenesis which results in the production of melanin.

Clinical Trials

Three male volunteers took part in a pilot Phase I clinical trial that was done at the University of Arizona Pharmacology dept. This 1996 study found out that Oxytocin. The study reported that the side effects were manageable at a dose of 0.025 mg. /kg. These results were reinforced by a 2000 study conducted at the same university, but this time at the Section of Urology, which studied the effect of Melanotan 2. Scientists have also studied the effect of melanotan 2 on dietary habits by investigating lab mice. They observed an activation of the central melanocortin in mice injected with MT-2. Over a period of six days, the mice reduced in weight as a result of the adipose tissue in the viscera suppressing the intake of calories. This means that melanotan 2 may have positive effects in overweight and obese people. It was also established that oxygen consumption in overweight animals increased, together with a higher rate of fat metabolism in the muscles.


No medical formulation or compound of MT-2 has been authorized to be used anywhere else apart from clinical trials.